Generate QR code
Open Access
Subscription Access
Current aspects of the development of peripartal cardiomyopathy
https://doi.org/10.30629/0023-2149-2025-103-7-493-498
Abstract
Despite extensive research aimed at studying the causes of peripartal cardiomyopathy, it is currently accepted to consider this disease as a cardiac pathology of unknown etiology.
Objective: to conduct a literature review to study the pathogenetic features of the development of peripartal cardiomyopathy and to analyze a series of clinical cases.
Research methodology. As part of the assessment of the pathogenetic mechanisms of PPCM development, a multi-stage approach to data collection and analysis was implemented, including both domestic and foreign sources. Information was searched in international databases such as PubMed, Scopus, Web of Science and Cochrane Library, as well as in Russian databases, including eLibrary, to account for all relevant and significant publications. The search used keywords and combinations such as peripartal cardiomyopathy, prolactin, STAT3, sFlt-1, VEGF, matrix metalloproteinases, in English and Russian. Special attention was paid to papers published over the past 15 years, with an emphasis on research conducted over the past 5 years to reflect all pathogenetic aspects of the development of PPCM. Both primary and secondary clinical studies and data from real clinical practice were included. Additionally, an analysis of domestic and foreign regulatory documents and recommendations was carried out in order to assess the possibilities of solving the clinical problem of PPCM.
Results. Current data indicate the need to integrate pathogenetic mechanisms, such as the effects of prolactin, STAT3, MMP and other molecules, into clinical practice for more effective diagnosis and treatment of PPCM. The analyzed studies show that PPCM requires an integrated approach to examination and treatment, as it can have various manifestations, and can also have serious consequences for the health of the mother and child. Due to the growing awareness of PPCM, its etiopathogenetic mechanisms should be further investigated.; Further clinical studies are needed to develop clear treatment protocols and recommendations that will help improve outcomes for this category of individuals.
About the Authors
L. D. Khidirova
Novosibirsk State Medical University of the Ministry of Health of the Russia ; Novosibirsk Regional Clinical Cardiology Dispensary
Russian Federation
Russian Federation
Lyudmila D. Khidirova — Doctor of Medical Sciences, Professor of the Department of Pharmacology, Clinical Pharmacology and Evidence-based Medicine; Leading cardiologist of the Polyclinic Department
Novosibirsk
S. I. Kalashnikova
Novosibirsk State Medical University of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Svetlana I. Kalashnikova — а 6 -year student
Novosibirsk
A. E. Goncharova
Novosibirsk State Medical University of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Alina E. Goncharova — a 6 -year student
Novosibirsk
References
1. Pfeffer T.J., Hilfiker-Kleiner D. Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. Curr. Probl. Cardiol. 2018;43(9):364-388. DOI: 10.1016/j.cpcardiol.2017.10.005
2. Rudaeva E.V., Moses V.G., Kashtalap V.V., Zakharov I.S., Elgina S.I., Rudaeva E.G. Congenital heart defects and pregnancy. Fundamental and clinical medicine. 2019;4(3):102– 112. (In Russian).
3. Shifman E.M., Kulikov A.V., Oyezov A.M., Ronenson A.M. Peripartum cardiomyopathy. Bulletin of obstetric anesthesiology. 2023;2:4–17. (In Russian).
4. Sliwa K., Mebazaa A., Hilfiker-Kleiner D. et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EUR Obser-vational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur. J. Heart Fail. 2017;19(9):1131–1141. DOI: 10.1002/ejhf.780
5. Kolte D., Khera S., Aronow W.S. et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J. Am. Heart Assoc. 2014;3:1– 13. DOI: 10.1161/JAHA.114.001056
6. Burduli N.M. Simultaneous development of peripartum cardiomyopathy and HELP syndrome. Clinical medicine. 2022;100(10):555–560. (In Russian).
7. Sliwa K., Hilfiker-Kleiner D., Petrie M.C. et al. Current state of k nowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopat hy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. 2010:767–778. DOI: 10.1093/eurjhf/hfq120
8. Zhang F. The research into the clinical characteristics of peripartum cardiomyopathy. Heart. 2012;98:165–6. DOI: 10.1136/heartjnI-2012-302920j.17
9. Haghikia A., Podewski E., Libhaber E. et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 2013;108(4):366. DOI: 10.1007/s00395-013-0366-9
10. Sliwa K., Mebazaa A., Hilfiker-Kleiner D. et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur. J. Heart Fail. 2017;19(9):1131–1141. DOI: 10.1002/ejhf.780
11. Mebazaa A., Seronde M.F., Gayat E. et al. Imbalanced angiogenesis in peripartum cardiomyopathy-diagnostic value of placenta growth factor. Circ. J. 2017;81(11):1654–1661. DOI: 10.1253/circj.CJ-16-1193
12. Madonov P.G., Khidirova L.D., Kazantseva V.D. Features of modern diagnostics and pharmacotherapy of peripartum cardiomyopathy. Journal of Siberian Medical Sciences. 2021;(4):134–148. (In Russian). DOI: 10.31549/2542-1174-2021-4-134-148
13. Vatutin N.T., Taradin G.G., Popelnukhina L.G. Treatment of peripartum cardiomyopathy (literature review). Archive of Internal Medicine. 2017;5:340–349. (In Russian).
14. Blauwet L.A., Cooper L.T. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97:1970–1981. DOI: 10.1136/heartjnl-2011-300349
15. Halkein J., Tabruyn S.P., Ricke-Hoch M. et al. Micro RNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 2013;123:2143–2154. DOI: 10.1172/JC164365
16. Hilfiker-Kleiner D., Kaminski K., Podewski E. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589-600. DOI:10.1016/j.cell.2006.12.036
17. Levine R.J., Maynard S.E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004;350(7):672–683. DOI: 10.1056/NEJMoa031884
18. Mebazaa A. et al. Imbalanced angiogenesis in peripartum cardiomyopathy diagnostic value of placenta growth factor. Circulation Journal. 2017. CJ-16-11931 DOI:10.1253/circj.CJ-16-1193
19. Macotela Y., Aguilar M.B., Guzman-Morales J et al. Matrix metallo proteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J. Cell Sci. 2006;119(9):1790–1800. DOI: 10.1242/jcs.02887
20. Ware J.S., Li J., Mazaika E. et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N. Engl. J. Med. 2016;374(3):233–241. DOI: 10.1056/NEJMoa1505517
21. Lee Y.Z.J., Judge D.P. The role of genetics in peripartum cardiomyopathy. J. Cardiovasc. Transl. Res. 2017;10(5–6):437–445. DOI: 10.1007/s12265-017-9764-у
22. Grigorieva K.N.; Bitsadze V.O. D. Khizroeva D.H. Metalloproteinases as biochemical markers of pregnancy maintenance. Obstetrics, gynecology, reproductive medicine. 2022;16(1):38–47. (In Russian). DOI:10.17749/2313-7347/ob.gyn.rep.2022.275
23. Kazantseva V.D., Khidirova L.D., Kokoulina N.A. Current understanding of pathophysiological mechanisms of peripartal cardiomyopathy. Medical alphabet. 2021;(17):76–80. (In Russian). DOI: 0.33667/2078-5631-2021-17-76-80
24. DeLeon-Pennell K.Y., Tian Y., Zhang B. et al. Cd36 is a matrix metalloproteinase-9 substrate that stimulates neutrophil apoptosis and removal during cardiac remodeling. Circ. Cardiovasc. Genet. 2016;9:14–25. DOI: 10.1161/circgenetics.115.001249
25. Syundyukova E.G., Chulkov V.S., Ryabikina M.G. Preeclampsia: The Modern State of the Problem. Doctor.Ru. 2021;20(1):11–16. (In Russian). DOI: 10.31550/1727-2378-2021-20-1-11-16
26. Palei A.C., Sandrim V.C., Cavalli R.C., Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase TIMP-1 and TIMP-2 in preeclampsiaand gestational hypertension. 2008;41(10–11):875–80. DOI: 10.1016/j.clinbiochem.2008.04.015
27. Chen J.R.A. Khalil, Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia, Prog. Mol. Biol. Transl. Sci. 2017;148:87–165. DOI:10.1016/bs.pmbts.2017.04.001
28. Lavee M., Goldman S., Daniel-Spiegel E., Shalev E. Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Reprod. Biol. Endocrinol. 2009;7:85. DOI:10.1186/1477-7827-7-85
29. Poon L.C., Stratieva V., Piras S., Piri S., Nicolaides K.H. Hyper tensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat. Diagn. 2010;30(3):216–23.
30. Tarca AL., Romero R., Benshalom-Tirosh N., NG., Gudicha DW., Done B., Pacora P., Chaiworapongsa T., Panaitescu B., Tirosh D., Gomez-Lopez N., Draghici S., Hassan SS., Erez O. The prediction of early preeclampsia: Results from a longitudinal proteomics study. Plos One. 2019;14(6):1–34 DOI:10.1371/journal.pone.0217273
31. Ilyina Yu.V., Fedorova T.A., Loshchin V.N. et al. Peripartum cardiomyopathy: clinical observation. Sechenovsky Bulletin. 2020;11(1):71–77. (In Russian).
32. Babakekhyan M.V., Stepanov E.D., Zazerskaya I.E. Clinical case of a patient with peripartum cardiomyopathy. Russian Journal of Cardiology. 2023:28:21 (In Russian).
33. Galyavich A.S., Tereshchenko S.N., Uskach T M et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russian). DOI: 10.15829/1560-4071-2024-6162
Review
For citations:
Khidirova L.D., Kalashnikova S.I., Goncharova A.E. Current aspects of the development of peripartal cardiomyopathy. Clinical Medicine (Russian Journal). 2025;103(7):493-498. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-7-493-498
Views:
52
Email this article 